NCT07399600 (P-TMS MetALD) is a NA clinical trial of Individually Targeted rTMS in Liver Diseases, Alcoholic, sponsored by The Affiliated Hospital of Hangzhou Normal University.

Who is sponsoring NCT07399600?

NCT07399600 is sponsored by The Affiliated Hospital of Hangzhou Normal University.

What drugs are being tested in NCT07399600?

Interventions in NCT07399600: Individually Targeted rTMS, Conventional rTMS, Transcranial Magnetic Stimulation Sham.

What condition does NCT07399600 study?

NCT07399600 studies Liver Diseases, Alcoholic, Fatty Liver, Metabolic Syndrome.

Is NCT07399600 still recruiting?

NCT07399600 is currently not yet recruiting. Last updated 10 February 2026.

Last reviewed 2026-02-10 · How we verify

NCT07399600: P-TMS MetALD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease

Not yet recruiting NA Last updated 10 February 2026

What this trial tests

NA trial testing Individually Targeted rTMS in Liver Diseases, Alcoholic in 105 participants. Not yet recruiting.

Timeline

1 February 2026

Primary endpoint
31 August 2027

31 December 2027

Quick facts

Lead sponsor	The Affiliated Hospital of Hangzhou Normal University
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	105
Start date	1 February 2026
Primary completion	31 August 2027
Estimated completion	31 December 2027
Sites	1 location across China

Drugs / interventions tested

Individually Targeted rTMS
Conventional rTMS
Transcranial Magnetic Stimulation Sham — full drug profile →

Conditions studied

Liver Diseases, Alcoholic — all drugs for Liver Diseases, Alcoholic →
Fatty Liver — all drugs for Fatty Liver →
Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

The Affiliated Hospital of Hangzhou Normal University

Who can join

Adults 18 to 65, any sex, with Liver Diseases, Alcoholic or Fatty Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, works to treat Metabolic dysfunction-associated and alcohol-associated liver disease (MetALD). The main questions it aims to answer are: * Can rTMS effectively treat MetALD? * Is an individualized, precision-targeted rTMS approach more effective than the standard rTMS method? * What changes in brain activity are associated with the treatment? Researchers will compare three different types of stimulation: * Group A: Individualized rTMS targeting a deep brain reward area (the Nucleus Accumbens) based on each participant's brain scan (fMRI). * Group B: Standard rTMS applied using the traditional "5 cm" rule for positioning. * Group C: Sham (placebo) rTMS, which mimics the procedure but delivers no significant magnetic stimulation. Participants will: * Be randomly assigned to one of the three groups (A, B, or C). * Undergo an MRI brain scan before starting treatment. * Receive a total of 20 rTMS sessions, completing at least 4 sessions per week. * Have additional MRI scans and clinical assessments halfway through and immediately after the treatment course. * Attend follow-up visits at 1, 3, and 6 months after treatment completion to assess long-term effects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Diseases, Alcoholic

Currently open trials in the same condition.

NCT06493773 — Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial · NA · recruiting
NCT06613698 — A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Y · Phase 2 · recruiting
NCT03308916 — Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers · NA · recruiting

Other The Affiliated Hospital of Hangzhou Normal University trials

Trials by the same sponsor.

NCT07241195 — A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From · not yet recruiting
NCT07233486 — A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD · NA · recruiting
NCT06201572 — The Value of TOI in Evaluating Renal Function Damage in Hypertensive Emergency Patients · unknown
NCT06135584 — Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07399600 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Hangzhou Normal University
Last refreshed: 10 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07399600.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing